Business Context and Reporting Period
Hercules Capital, Inc. (Hercules) is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and a Regulated Investment Company (RIC). The company focuses on providing senior secured loans to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors. This summary covers the quarterly period ended September 30, 2017.
Key Financial Metrics
| Metric | Q3 2017 (Three Months) | YTD 2017 (Nine Months) | YTD 2016 (Nine Months) |
|---|---|---|---|
| Total Investment Income | $45.9 million | $140.7 million | $127.6 million |
| Net Investment Income | $24.0 million | $71.9 million | $67.2 million |
| Net Realized Gain (Loss) | $(24.5) million | $(26.9) million | $3.4 million |
| Net Unrealized Appreciation (Depreciation) | $33.6 million | $15.6 million | $(16.1) million |
| Net Increase in Net Assets from Operations | $33.1 million | $60.6 million | $54.6 million |
| Net Asset Value (NAV) per Share | $10.00 | $10.00 (End of Period) | $9.86 (End of Period) |
| Total Assets | $1.58 billion | $1.58 billion | $1.46 billion (Dec 31, 2016) |
| Total Liabilities | $746.7 million | $746.7 million | $676.3 million (Dec 31, 2016) |
| Cash and Cash Equivalents | $140.6 million | $140.6 million | $13.0 million (Dec 31, 2016) |
Material Changes vs. Prior Period
- Realized Losses: The company recognized a net realized loss of $26.9 million for the nine months ended September 30, 2017, compared to a net realized gain of $3.4 million in the same period in 2016. This shift was driven by gross realized losses of $39.8 million, primarily from the liquidation or write-off of warrant and equity investments in 19 portfolio companies and debt investments in four companies. Notable write-offs included SkyCross, Inc. and Tectura Corporation warrants.
- Unrealized Gains: Net unrealized appreciation of $15.6 million for the nine months ended September 30, 2017, contrasted with $16.1 million of depreciation in the prior year. This improvement was largely due to the reversal of prior period collateral-based impairments on debt investments (including Sungevity, Inc.) and market yield adjustments.
- Debt Structure: The company fully redeemed its 2019 Notes ($110.4 million principal) in February 2017. Conversely, it issued $230.0 million in 2022 Convertible Notes in January 2017. Total debt principal outstanding increased from $667.7 million at year-end 2016 to $744.2 million at September 30, 2017.
- Liquidity: Cash and cash equivalents increased significantly from $13.0 million at December 31, 2016, to $140.6 million at September 30, 2017, driven by proceeds from the Convertible Notes issuance and equity offerings, offset by distributions and investment purchases.
Guidance, Outlook, and Risks
- Portfolio Composition: As of September 30, 2017, the portfolio was heavily weighted toward Drug Discovery & Development (27.7%) and Software (20.0%). Approximately 96.7% of the debt portfolio was priced at floating rates, positioning the company to benefit from rising interest rates.
- Investment Grading: The weighted average investment grading improved to 2.24 (on a cost basis) from 2.41 at year-end 2016. There were no investments graded as "5" (highest risk) at September 30, 2017, compared to 5.6% of the portfolio at year-end 2016.
- Non-Accrual Status: Five debt investments were on non-accrual status with a cumulative cost of $14.0 million and fair value of $3.0 million, a decrease from $43.9 million in cost at year-end 2016.
- Capital Resources: The company maintains an At-The-Market (ATM) equity distribution agreement with 11.2 million shares available. It also has $190.2 million in SBA-guaranteed debentures outstanding through its SBIC subsidiaries.
- Risks: Key risks include the volatility of private market valuations (Level 3 assets), the ability of portfolio companies to achieve liquidity events (IPOs/M&A), and the impact of interest rate fluctuations on borrowing costs versus asset yields.
Key Facts for Investor Verification
- Realized Loss Drivers: Verify the specific portfolio companies contributing to the $39.8 million in gross realized losses, particularly the write-offs of SkyCross, Inc. and Tectura Corporation warrants, to assess credit quality trends.
- Unrealized Reversals: Confirm the magnitude of the $52.0 million reversal of prior period collateral-based impairments, specifically regarding the Sungevity, Inc. conversion, to understand the sustainability of the unrealized gain.
- Debt Maturity Profile: Review the maturity schedule of the $744.2 million in outstanding debt, noting the 2021 Asset-Backed Notes and the 2022 Convertible Notes, to assess refinancing risks.
- Unfunded Commitments: Note the $46.3 million in unfunded contractual commitments available at the request of portfolio companies, which represents future capital deployment obligations.
- Dividend Coverage: Verify the tax attributes of the $0.31 per share distribution declared for the quarter, as the company aims to distribute 100% of spillover earnings to maintain RIC status.